Related Experiment Video
Updated: May 16, 2026
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
Solid lipid nanoparticles of anticancer drugs against MCF-7 cell line and a murine breast cancer model
Yu-Gang Zhuang1, Bing Xu, Fang Huang
1Department of Emergency, Shanghai Tenth People's Hospital, Shanghai, P.R.China. mmherofg@gmail.com
Abstract:
To develop some promising anticancer drug loaded solid lipid nanoparticles (SLN) for further clinical application, SLN carrying mitoxantrone (MTO), paclitaxel (PCT), methotrexate (MTX) were prepared and their cytotoxic effects on the human breast cancer cell line, MCF-7 were investigated. The 50 % inhibitory concentration (IC50) values were interpolated from growth curves obtained by MTT assay. Moreover, the inhibition effects of the drugs incorporated in SLN on a murine breast cancer model induced by MCF-7 cells were further examined. In vitro cytotoxicity of MTO loaded SLN (IC50/72h=1.25 +/- 0.19 microM vs 2.13 +/- 0.37 microM) and MTX loaded SLN (IC50/72h = 93.80 +/- 6.54 nM vs 153.16 +/- 11.54 nM) was higher than that of free drug formulations. In vitro cytotoxicity of PCT-loaded SLN and free drug formulation IC50/72 h were similar. Then, the MCF-7 breast cancer model in mice was established. In mice treated with SLN injections for a month, tumor was significantly inhibited. Mean tumor size of mice treated with SLN was significantly smaller than that with free drug (P<0.05). Additionally, the percent inhibition of mice treated with SLN was obviously lower than that with free drug (P<0.05). Therefore, the conclusion can be drawn that anticancer drugs carried by SLN, including mitoxantrone, methotrexate and paclitaxel, may be more effective than free anticancer drugs for breast cancer treatment.
Insights
Solid lipid nanoparticles (SLN) loaded with anticancer drugs like mitoxantrone and methotrexate showed enhanced efficacy against breast cancer cells in vitro and in vivo. These drug-loaded SLN may offer a more effective treatment strategy compared to free drugs.
Area of Science:
- Nanotechnology
- Oncology
- Pharmacology
Background:
- Solid lipid nanoparticles (SLN) are a promising drug delivery system for cancer therapy.
- Developing effective drug delivery for breast cancer remains a critical challenge.
- Investigating novel formulations to improve anticancer drug efficacy is essential.
Purpose of the Study:
- To develop and evaluate anticancer drug-loaded SLN for breast cancer treatment.
- To compare the in vitro and in vivo efficacy of SLN-encapsulated drugs versus free drugs.
- To assess the potential of SLN for enhanced delivery of mitoxantrone, paclitaxel, and methotrexate.
Main Methods:
- Preparation of SLN loaded with mitoxantrone (MTO), paclitaxel (PCT), and methotrexate (MTX).
- In vitro cytotoxicity assessment using MTT assay on MCF-7 human breast cancer cells.
- In vivo evaluation of tumor inhibition in a murine breast cancer model induced by MCF-7 cells.
Main Results:
- SLN loaded with MTO and MTX demonstrated significantly higher in vitro cytotoxicity compared to their free formulations.
- In vitro cytotoxicity of PCT-loaded SLN was comparable to the free drug.
- In vivo studies showed significant tumor inhibition in mice treated with SLN, with smaller tumor size and greater inhibition percentage compared to free drugs.
Conclusions:
- Anticancer drugs encapsulated in SLN, including MTO, MTX, and PCT, show potential for improved breast cancer treatment.
- SLN-based drug delivery may enhance the therapeutic efficacy of existing anticancer agents.
- Further clinical applications of drug-loaded SLN for breast cancer are warranted.
